Treating myeloma: the future is already here!-Reference-Cited by-同舟云学术

Treating myeloma: the future is already here!

Published:2012-08-30 Issue:9 Volume:120 Page:1754-1756
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Landgren Ola¹,Korde Neha¹

Affiliation:

1. NATIONAL CANCER INSTITUTE

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/120/9/1754/1362749/zh803512001754.pdf

Reference5 articles.

1. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.;Jakubowiak;Blood,2012

2. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.;Richardson;Blood,2010

3. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.;Korde;Blood,2011

4. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? [published online ahead of print June 18, 2012].;Usmani;Leukemia

5. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.;Nair;Blood,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status;Seminars in Oncology;2016-12

2. Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells;PLOS ONE;2015-06-19

3. Landgren O, Korde N. Treating myeloma: the future is already here! Blood. 2012;120(9):1754-1756.;Blood;2014-03-06

4. Improved long-term survival in multiple myeloma up to the age of 80 years;Leukemia;2014-01-14

5. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity;Blood;2013-08-08